Dublin, April 02, 2026 (GLOBE NEWSWIRE) — The “Adrenocortical Carcinoma Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The adrenocortical carcinoma market is on a growth trajectory, with projections showing an increase from $3.76 billion in 2025 to $3.92 billion in 2026, at a CAGR of 4.4%. This growth stems from heightened diagnosis through imaging technologies, an expansion of specialized cancer research centers, and increased patient awareness.
Looking toward 2030, the market is expected to reach $4.62 billion, with a CAGR of 4.2%, supported by advancements in targeted therapies and minimally invasive procedures, as well as the adoption of combination therapy protocols.
The rise in the prevalence of rare cancers is a significant driver of this market’s expansion. Advances in diagnostic technologies have improved early detection, especially in rare cancer types like adrenocortical carcinoma (ACC), which are aggressive and have specific diagnostic and therapeutic needs. A report by the International Agency for Research on Cancer highlights that rare cancers comprise about 25% of all cancer diagnoses globally.
Key market players are focusing on innovative therapies, including small-molecule drugs that target specific tumor pathways. Orphagen Pharmaceuticals recently announced FDA’s Rare Pediatric Disease Designation for its investigational drug OR-449, targeting pediatric ACC. This underscores ongoing innovation in the treatment landscape.
In business developments, Esteve Pharmaceuticals acquired HRA Pharma Rare Diseases, expanding its portfolio to address rare diseases like adrenocortical carcinoma and enhancing global market reach. Notable companies in this sector, such as HRA Pharma, Servier Laboratories, Roche Holding, and others, are playing pivotal roles in advancing ACC treatment.
Geographically, North America led the market in 2025, with Asia-Pacific forecasted as the fastest-growing region through 2030. Significant growth is anticipated across regions including Western and Eastern Europe, South America, and the Middle East.
Reasons to Purchase:
- Gain a global perspective with this extensive report covering 16 geographies.
- Evaluate the impact of macro factors such as geopolitical conflicts, trade policies, inflation, and regulatory changes.
- Develop regional and country strategies based on detailed local data.
- Identify promising growth segments for investment.
- Utilize forecast data to outpace competitors, understanding market drivers and trends.
- Analyze end-user data to better understand customer needs.
- Benchmark against competitors using metrics like market share, innovation, and brand strength.
- Measure market potential with total addressable market (TAM) analysis.
- Support presentations with reliable data, updated and accompanied by an Excel data sheet for analysis.
Markets Covered:
1) By Type: Localized; Metastatic
2) By Therapy: Surgery; Chemotherapy; Targeted and Radiation Therapy
3) By End User: Hospitals; Oncology Centers; Medical Centers
Subsegments: Includes breakdowns by type, therapy, and metastasis stages.
Companies Mentioned: Key players include HRA Pharma, Servier Laboratories, Roche, Merck, AstraZeneca, Eli Lilly, Sanofi, Ipsen, and others.
Countries: Includes markets like Australia, Brazil, China, France, Germany, India, and more.
Regions: Spanning Asia-Pacific, Southeast Asia, Europe, North America, and others.
Time Series: Data spans five years historic and ten years forecast.
Data: Includes data on market size, growth, GDP ratios, and expenditure per capita.
Data Segmentation: Covers country, regional data, market share, and competitor analysis.
Delivery Format: Available in Word, PDF, or Interactive + Excel Dashboard.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $3.92 Billion |
| Forecasted Market Value (USD) by 2030 | $4.62 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
The companies featured in this Adrenocortical Carcinoma market report include:
- HRA Pharma S.A.
- Servier Laboratories
- Roche Holding AG
- Merck & Co. Inc.
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Eli Lilly and Company
- Sanofi S.A.
- Ipsen S.A.
- Exelixis Inc.
- Tempest Therapeutics Inc.
- Orphagen Pharmaceuticals Inc.
- Millendo Therapeutics Inc.
- Pfizer Inc
- Novartis AG
- Bayer AG
- Takeda Pharmaceutical Company
- Astellas Pharma Inc.
- Johnson & Johnson
- Gilead Sciences
For more information about this report visit https://www.researchandmarkets.com/r/qhak86
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Adrenocortical Carcinoma Market
